Not only have all the patients survived, according to Pluristem, but four of them showed improvement in respiratory parameters. JPOST
Pluristem’s PLX cells are “allogeneic mesenchymal-like cells that have immunomodulatory properties,” meaning they induce the immune system’s natural regulatory T cells and M2 macrophages, the company explained in a previous release. The result could be the reversal of dangerous overactivation of the immune system. This would likely reduce the fatal symptoms of pneumonia and pneumonitis (general inflammation of lung tissue).
Could the damaged Red Blood Cells be causing this:
'Cardiac calls' to 911 in New York City surge, and they may really be more COVID cases NBCnews
Since the beginning of the coronavirus outbreak, residents of hard-hit New York City have been talking about ambulance sirens and how the wailing never seems to stop.
They're not imagining things — but the reality is even grimmer than some may have guessed. A huge number of those ambulances are responding to fatal or near-fatal heart attacks suffered by New Yorkers whose true health issue may be COVID-19, the disease associated with the coronavirus.
Emergency Medical Services, the part of the fire department that runs the city's paramedic response, is responding to three or four times its average daily number of cardiac calls, with each call almost twice as likely to involve a death.
Read full article at link above
Low Oxygen Danger for the Heart
UCSF.edu/news
Running low on oxygen is a major danger for any of your body’s tissues, but the heart is particularly sensitive to such hypoxic conditions, which can lead to long-term tissue damage or even heart attacks.
In new studies conducted at UC San Francisco, a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.
“Any tissue with compromised blood flow, whether due to trauma, stroke, or heart disease, could potentially be targeted by a treatment like this,” said Emin Maltepe, MD, PhD, associate professor of pediatrics at UCSF and co-senior author of the paper.
The new drug, called OMX-CV, was developed by Omnio Inc. – a biopharmaceutical company developing oxygen-delivery therapeutics for the treatment of cancer, cardiovascular diseases, trauma and other conditions in which low oxygen levels, or hypoxia, negatively impact disease outcomes.
Read more at link above
No comments:
Post a Comment